SCD and Varicose veins: The effects of restoring the endothelial glycocalyx following mesoglycan administration were indirectly demonstrated by a reduction in SCD-1 (157.1 [140.5–179.4] ng/mL vs. 187.4 [167.2–235.7] ng/mL, p = 0.0005) and SDC-4 (42.22 [34.56–53.72] ng/mL vs. 56.75 [46.04–71.71] ng/mL, p = 0.0002) at the site of varicose veins, with similar findings observed in the systemic circulation (SCD-1: 148.5 [129.0–176.0] ng/mL vs. 177.2 [161.7–203.2] ng/mL, p = 0.0007; SDC-4: 37.07 [33.41–49.26] ng/mL vs. 51.74 [38.27–62.31] ng/mL, p = 0.065).